Home » Newsletters » BioWorld Science

BioWorld Science

March 10, 2008

View Archived Issues

Experiments demonstrate alemtuzumab potential in ovarian cancer

AZD-0530 checks activity of MUC16+ ovarian cancer cells

Vermillion research identifies potential markers of ovarian cancer

PharmAthene reports results from initial pharmacokinetic studies of Protexia

Akela initiate phase I clinical trial of Edacs abuse deterrent opioid

IRD reports results from Senegalese study of the ELISPOT and TST tests for TB

Medarex reviews highlights of fourth quarter and full-year 2007

Recent patents divulge novel analgesic agents

New gene involved in ALS identified

Cortex receives German approval for two Ampakine CX-717 trials

Eden Biodesign and Stealthyx to develop enhanced treatment for rheumatoid arthritis

GammaCan presents update in VitiGam program for melanoma

Gilead submits MAA for aztreonam lysine 75 mg powder for nebulizer solution

Phase I NVC-422 trial commences in catheter-associated urinary tract infections

Singulex enters collaboration with Novartis Pharma for Erenna biomarker detection platform

Health Canada grants approval to Chemokine for phase II study of CTCE-9908 in liver cancer

ProMetic reports results from phase II trial of PBI-1402 in chemotherapy-induced anemia

Metabolon launches third-generation metabolomics platform for biochemical profiling

FDA approves Biocompatibles' phase II trial of Paragon Bead in hepatic colorectal metastases

New treatment options for cardiovascular disorders described in patent literature

Novel therapeutic agents for HIV infection disclosed in recent patents

Keryx reports negative results from SUN-MICRO phase III clinical trial of Sulonex

Genta enters worldwide licensing agreement with Daiichi Sankyo for taxane drug tesetaxel

FDA grants marketing approval to Spectrum for Levoleucovorin for injection

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...